Literature DB >> 12230315

Medical management of obesity.

Robert F Kushner1.   

Abstract

Obesity is the most prevalent and serious nutritional disease among western countries and is rapidly replacing undernutrition as the most common form of malnutrition in the world. Approximately 300,000 deaths a year are currently associated with overweight and obesity, second only to cigarette smoking as a leading cause of preventable death in the United States. Obesity effects 9 organ systems and is a risk factor for gastroesophageal reflux disease, nonalcoholic fatty liver disease, cholelithiasis, and colon cancer. Evidence-based guidelines on the identification, evaluation, and treatment of overweight and obesity have recently been developed by the National Institutes of Health to help practitioners effectively manage their patients. The body mass index is used to classify weight status and risk of disease. Treatment for obesity includes lifestyle management, consisting of diet therapy, physical activity, and behavioral modification, and may include pharmacotherapy or surgery based on level of risk. Currently only 2 medications, sibutramine and orlistat, are approved for long-term use. An initial weight loss of 10% of body weight achieved over 6 months is a recommended target. This article reviews the evaluation and management of the adult obese patient.

Entities:  

Mesh:

Year:  2002        PMID: 12230315

Source DB:  PubMed          Journal:  Semin Gastrointest Dis        ISSN: 1049-5118


  11 in total

1.  Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis.

Authors:  Nimer Assy; Osamah Hussein; Zied Abassi
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

2.  Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH).

Authors:  Osamah Hussein; Masha Grosovski; Sorina Schlesinger; Sergio Szvalb; Nimer Assy
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

Review 3.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

4.  Redefining contraindications to laparoscopic colorectal resection for high-risk patients.

Authors:  John H Marks; Ulana B Kawun; Wajdi Hamdan; Gerald Marks
Journal:  Surg Endosc       Date:  2008-03-18       Impact factor: 4.584

Review 5.  Impact of treating the metabolic syndrome on chronic kidney disease.

Authors:  Varun Agrawal; Aashish Shah; Casey Rice; Barry A Franklin; Peter A McCullough
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

6.  Obese state leads to elevated levels of TGF-beta and COX isoforms in platelets of Zucker rats.

Authors:  Jayadev Raju; Gagan Bajaj; Jennifer Chrusch; Ranjana P Bird
Journal:  Mol Cell Biochem       Date:  2006-02-14       Impact factor: 3.396

7.  Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Hu Wang; Li Wang; Yujia Cheng; Zhiqing Xia; Yifeng Liao; Jiang Cao
Journal:  Biomed Rep       Date:  2018-05-22

8.  Micronutrient Gaps in Three Commercial Weight-Loss Diet Plans.

Authors:  Matthew G Engel; Hua J Kern; J Thomas Brenna; Susan H Mitmesser
Journal:  Nutrients       Date:  2018-01-20       Impact factor: 5.717

9.  Hawthorn ethanolic extracts with triterpenoids and flavonoids exert hepatoprotective effects and suppress the hypercholesterolemia-induced oxidative stress in rats.

Authors:  Ali Rezaei-Golmisheh; Hassan Malekinejad; Siamak Asri-Rezaei; Amir Abbas Farshid; Peyman Akbari
Journal:  Iran J Basic Med Sci       Date:  2015-07       Impact factor: 2.699

10.  Saponins and Flavonoids from Adzuki Bean (Vigna angularis L.) Ameliorate High-Fat Diet-Induced Obesity in ICR Mice.

Authors:  Rui Liu; Yinan Zheng; Zongwei Cai; Baojun Xu
Journal:  Front Pharmacol       Date:  2017-09-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.